Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback